CONBA(SH:600572)2022-04-25 16:00Financial Performance - The company achieved operating revenue of RMB 1,594,713,433.17 in Q1 2022, a slight increase of 0.23% year-on-year, and a comparable growth of 16.43% after excluding revenue from Jiangxi Zhenzhiming Pharmaceutical Co., Ltd.[8] - Net profit attributable to shareholders reached RMB 101,533,524.59, representing a significant increase of 112.25% compared to the same period last year[11] - The self-care product business generated sales revenue of RMB 732 million, a decline of 10.50% year-on-year, but a comparable growth of 14.55% after excluding Zhenzhiming's revenue[9] - Prescription drug sales amounted to RMB 593 million, up 5.07% year-on-year, with a comparable growth of 13.57% after excluding Zhenzhiming's sales[9] - Total revenue for Q1 2022 was approximately ¥1.59 billion, a slight increase from ¥1.59 billion in Q1 2021[31] - Net profit for Q1 2022 reached approximately ¥130.98 million, compared to ¥76.54 million in Q1 2021, reflecting a significant year-over-year increase[34] - The total comprehensive income attributable to the parent company was CNY 101,491,999.71, compared to CNY 47,834,425.32 in the same period last year, representing an increase of approximately 112.5%[37] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of RMB 50,391,186.16, a decrease of 68.70% compared to the previous year[5] - The company's cash and cash equivalents as of March 31, 2022, amounted to RMB 2,758,907,120.00, an increase from RMB 2,487,257,698.65 at the end of 2021[26] - Cash inflows from operating activities totaled CNY 1,240,655,082.08, down 15.0% from CNY 1,459,952,583.45 in the previous year[39] - Cash outflows from operating activities amounted to CNY 1,190,263,895.92, a decrease of 8.3% compared to CNY 1,298,976,978.00 last year[39] - The total cash and cash equivalents at the end of the period reached CNY 2,665,195,599.97, up from CNY 887,519,255.77 year-over-year[41] - The company's cash inflow from investment activities was CNY 15,348,953.42, down from CNY 207,229,200.00 in the previous year[50] - The ending balance of cash and cash equivalents reached $2,313,166,476.26, compared to $247,308,527.50 at the end of the previous period, indicating a substantial increase[53] Assets and Liabilities - Total assets at the end of the reporting period were RMB 11,288,234,488.21, an increase of 4.59% from the end of the previous year[8] - Total assets increased to approximately ¥11.29 billion in Q1 2022 from ¥10.79 billion in Q1 2021, indicating growth in the company's asset base[31] - Total liabilities rose to approximately ¥3.77 billion in Q1 2022 from ¥3.40 billion in Q1 2021, suggesting increased leverage[31] - Accounts receivable increased to RMB 1,360,484,563.68 from RMB 813,205,716.32 year-over-year[26] - Inventory as of March 31, 2022, was RMB 932,386,570.06, slightly up from RMB 923,412,089.32 at the end of 2021[26] - The total liabilities rose to CNY 2,803,469,466.75 from CNY 2,040,694,593.25, marking an increase of approximately 37.3%[48] Shareholder Information - The total number of common shareholders at the end of the reporting period was 109,607[18] - Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. holds 535,777,040 shares, accounting for 20.85% of total shares[18] - The second-largest shareholder, Kang En Bei Group Co., Ltd., holds 218,618,171 shares, representing 8.51%[18] Strategic Initiatives - The company plans to continue expanding its self-care product business and enhance its online retail operations to drive future growth[9] - A strategic cooperation framework agreement was signed with Kang Chen Pharmaceutical Group to enhance collaboration in various areas[25] Research and Development - Research and development expenses for Q1 2022 were approximately ¥44.40 million, up from ¥38.36 million in Q1 2021, highlighting a focus on innovation[34] - Research and development expenses increased to CNY 9,444,410.20 from CNY 8,802,823.51, representing a growth of about 7.3%[48]